Which statement correctly describes the scheduling of amobarbital, secobarbital, and pentobarbital when combined with non-controlled drugs or in suppository form?

Which statement correctly describes the scheduling of amobarbital, secobarbital, and pentobarbital when combined with non-controlled drugs or in suppository form?

• A. Schedule II
• B. Schedule IV
• C. Schedule III
• D. Not scheduled

Answer: (C)

When amobarbital, secobarbital, and pentobarbital are used without other drugs, they’re Schedule II because of their high abuse potential and accepted medical use with tight controls. If these barbiturates are combined with a non-controlled substance or formulated as a suppository, the product is placed in Schedule III. The presence of another active ingredient or the particular dosage form reduces the overall abuse risk compared to the pure barbiturate, so the regulatory level is lowered. In practice, combination or suppository forms are treated as Schedule III, while single-entity forms remain Schedule II.

When amobarbital, secobarbital, and pentobarbital are used without other drugs, they’re Schedule II because of their high abuse potential and accepted medical use with tight controls. If these barbiturates are combined with a non-controlled substance or formulated as a suppository, the product is placed in Schedule III. The presence of another active ingredient or the particular dosage form reduces the overall abuse risk compared to the pure barbiturate, so the regulatory level is lowered. In practice, combination or suppository forms are treated as Schedule III, while single-entity forms remain Schedule II.